SLFN11 overexpression in human MSCs reduced senescence in vitro and colitis in mice
In this abstract, overexpressing SLFN11 in human mesenchymal stem/stromal cells reduced senescence markers in vitro and, in a mouse colitis model, SLFN11-overexpressing cells protected better than control cells. The abstract reports no detectable tumorigenicity or chromosomal aberrations. [1]
Automatic summary · not editorially reviewed
The key findings
Long-term in vitro expansion of human MSCs triggers replicative and stress-induced senescence, which the study aimed to counter with SLFN11 overexpression. [1]
SLFN11 overexpression reduced DNA damage, reversed cell cycle arrest and improved proliferation, clonogenicity and stemness in human MSCs. [1]
In a DSS-induced mouse ulcerative colitis model, SLFN11-overexpressing MSCs protected better than control MSCs, and no tumorigenicity or chromosomal aberrations were detected. [1]
The source at a glance
- Study type / format
- In vitro cell study with a mouse disease model (abstract)
- Population / context
- Human mesenchymal stem/stromal cells in vitro and mice in a DSS-induced ulcerative colitis model
- Summary based on
- Study abstract
- Original publication
- July 6, 2026
Senescence of expanded human MSCs in vitro
The abstract states that mesenchymal stem/stromal cells (MSCs) are important for cellular therapy, but long-term expansion in the laboratory triggers replicative and stress-induced senescence, which weakens their stemness and therapeutic potential. The study asked whether the Schlafen 11 gene (SLFN11) protects human MSCs from senescence in vitro. SLFN11 was overexpressed in human MSCs using lentiviral transduction, and effects were assessed in replicative and stress-induced senescence models.
Supporting source [1]
Less DNA damage and better proliferation with SLFN11
According to the abstract, SLFN11 overexpression significantly attenuated senescence: DNA damage accumulation was reduced, cell cycle arrest was reversed, and proliferation, clonogenicity and stemness properties improved. Mechanistically, SLFN11 bound the RNA helicase DDX1 and attenuated mTOR/eIF4E signaling. In a mouse model of ulcerative colitis induced by DSS, SLFN11-overexpressing MSCs protected better than control MSCs, with fewer colonic lesions, maintained mucosal integrity and inhibited secretion of proinflammatory factors.
Supporting source [1]
Safety findings and limits of this abstract
The abstract reports that SLFN11-overexpressing MSCs showed no detectable tumorigenicity or chromosomal aberrations. It describes a non-canonical role for SLFN11 in protecting MSCs from senescence via the DDX1/mTOR/eIF4E axis and calls these cells a promising cell therapy source. These are the authors' conclusions from in vitro work and a mouse colitis model; the abstract gives no human treatment data, and the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from in vitro human MSC experiments and a mouse colitis model, with no human treatment data reported. The abstract does not report sample sizes, follow-up duration or statistical details.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhu XX, Luo Y, Xu JY, Yang X, Liu YS, Xiao JH. · europepmc.org · July 6, 2026